Technical Analysis for NBIX - Neurocrine Biosciences, Inc.

Grade Last Price % Change Price Change
C 93.53 -1.13% -1.07
NBIX closed up 2.9 percent on Friday, May 14, 2021, on 55 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Up
Historical NBIX trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish -1.13%
Crossed Above 50 DMA Bullish -1.13%
MACD Bullish Signal Line Cross Bullish -1.13%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.74%
Inside Day Range Contraction 1.74%
20 DMA Resistance Bearish 1.50%
50 DMA Resistance Bearish 1.50%
Lower Bollinger Band Walk Weakness 1.50%
Up 3 Days in a Row Strength 1.50%
Up 4 Days in a Row Strength 1.50%
Older End-of-Day Signals for NBIX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
20 DMA Support about 2 hours ago
Down 1% about 2 hours ago
50 DMA Resistance about 3 hours ago
Fell Below 50 DMA about 3 hours ago
50 DMA Support about 3 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Neurocrine Biosciences, Inc. Description

Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It develops drugs for endometriosis, tardive dyskinesia, uterine fibroids, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. The company's products in clinical development include Elagolix, a Phase III drug for endometriosis; Vesicular Monoamine Transporter 2 Inhibitor (VMAT2), a Phase II drug for movement disorders; CRF2 Peptide Agonist, a Phase II drug for cardiovascular diseases; CRF1 Antagonist, a Phase II drug for stress-related disorders; and Elagolix, a Phase II drug for uterine fibroids. Its research programs comprise G Protein-Coupled Receptor 119 (GPR119) for type II diabetes; VMAT2 for schizophrenia; gonadotropin-releasing hormone (GnRH) Antagonists for men's and women's health, and oncology; Antiepileptic Drugs for epilepsy, essential tremor, and pain; and G Protein-Coupled Receptors for other conditions. The company has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Boehringer Ingelheim International GmbH to research, develop, and commercialize small molecule GPR119 agonists for the treatment of Type II diabetes and other indications; and Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize indiplon in Japan. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Development Pain Diabetes Disorders Schizophrenia Cardiovascular Disease Alcohols Hormones Epilepsy Vascular Diseases Cardiovascular Diseases Ethers Related Disease Related Diseases Movement Disorders Related Disorders Transporter Boehringer Ingelheim I Diabetes Insomnia Endometriosis Fibroids Ii Diabetes Dyskinesia Gnrh Antagonists Pyrimidines Uterine Fibroid Uterine Fibroids Essential Tremor Gonadotropin Releasing Hormone Antagonist Neurocrine Biosciences

Is NBIX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 136.265
52 Week Low 86.02
Average Volume 1,110,008
200-Day Moving Average 101.68
50-Day Moving Average 94.12
20-Day Moving Average 94.19
10-Day Moving Average 91.86
Average True Range 3.38
ADX 25.05
+DI 13.69
-DI 19.13
Chandelier Exit (Long, 3 ATRs ) 89.36
Chandelier Exit (Short, 3 ATRs ) 97.32
Upper Bollinger Band 99.55
Lower Bollinger Band 88.83
Percent B (%b) 0.54
BandWidth 11.37
MACD Line -1.05
MACD Signal Line -1.09
MACD Histogram 0.0383
Fundamentals Value
Market Cap 8.84 Billion
Num Shares 93.4 Million
EPS 0.96
Price-to-Earnings (P/E) Ratio 98.23
Price-to-Sales 8.97
Price-to-Book 11.10
PEG Ratio 1.87
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 100.42
Resistance 3 (R3) 99.88 97.40 99.45
Resistance 2 (R2) 97.40 95.92 97.67 99.13
Resistance 1 (R1) 96.00 95.00 96.70 96.54 98.80
Pivot Point 93.52 93.52 93.87 93.79 93.52
Support 1 (S1) 92.12 92.04 92.82 92.66 90.40
Support 2 (S2) 89.64 91.12 89.91 90.07
Support 3 (S3) 88.24 89.64 89.75
Support 4 (S4) 88.78